{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-038686","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.234973+00:00","generated_at":"2026-06-04T07:47:42.474544+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cognition Therapeutics reports FY2023 net loss of $25.8M, cash runway through May 2025","bullets":["Net loss of $25.8M ($0.86 per share) for FY2023 vs $21.4M ($0.91 per share) in FY2022.","Cash and equivalents $29.9M at Dec 31, 2023; NIA grant funds of $67.5M remain available.","March 2024 follow-on offering raised ~$10.4M net, extending cash runway through May 2025.","Topline results from Phase 2 SHINE study (Alzheimer's) expected mid-2024; SHIMMER (DLB) in 2H2024.","R&D expenses rose to $37.2M from $30.3M, mainly due to Phase 2 trial activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-038686","json":"https://secwatch.observer/filing/0001104659-24-038686.json","markdown":"https://secwatch.observer/filing/0001104659-24-038686.md","text":"https://secwatch.observer/filing/0001104659-24-038686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/0001104659-24-038686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/tm249736d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:47:42.474544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb244f8ce235e1de949b19746f060dd2ce512994","claim":"COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income $25.8 million, EPS $(0.86) per basic and diluted share.","evidence_excerpt":"The Company reported a net loss of $25.8 million, or $(0.86) per basic and diluted share for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/0001104659-24-038686-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$25.8 million"},{"label":"EPS","value":"$(0.86) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}